USPTO 2015–2025 USPTO PatentsView US Corporation

Incyte Corporation

USPTO PatentsView assignee record - 652 granted patents across 22 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

652

Total patents granted

CPC technology areas

26.1

Avg claims per patent

+17%

5-year filing velocity

The verdict

Incyte holds 652 US patents across 22 technology areas, rank #693 of 50,000 tracked assignees.

#693
of 50,000 US assignees by volume: Top 3%
by Innovation Score (61.5/100): 26.1
avg claims per patent: +17%
filing velocity, last 5 yrs

Portfolio overview

Incyte Corporation has been granted 652 US utility patents between 2015 and 2025, placing Incyte Corporation at rank #693 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Incyte Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Incyte sits between Roche Diagnostics Operations, Inc. (654 patents, rank #689) and TIME Warner Cable Enterprises Llc (651 patents, rank #697) - the closest US assignees by grant volume. The composite Innovation Score of 61.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 351 grants, compared with 301 in the 2015–2019 window, a +17% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Incyte Corporation's 26.1 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 22 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Incyte Corporation against peers pursuing similar technology classes.

Roche Diagnostics…

654
psemi

654
Nederlandse Organ…

653
Hughes Network Sy…

652
University of Sou…

652
Incyte ◀

652
British Telecommu…

651
BYD

651
TIME Warner Cable…

651

What this shows Incyte holds 652 patents at rank #693, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Incyte

By rank, the assignees closest to #693 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Incyte's primary technology class.

Incyte's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

61 Top 3% higher than 97% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Incyte Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	43	6.6%
2016	57	8.7%
2017	72	11.0%
2018	64	9.8%
2019	65	10.0%
2020	58	8.9%
2021	54	8.3%
2022	65	10.0%
2023	64	9.8%
2024	70	10.7%
2025	40	6.1%

Which technologies does Incyte Corporation patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 605

C07D - HETEROCYCLIC COMPOUNDS 566

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 369

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 89

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 31

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 24

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 22

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 20

C07K - PEPTIDES 18

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 15

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 7

A01M - CATCHING, TRAPPING OR SCARING OF ANIMALS ; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS 5

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 4

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 3

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 2

Top 15 of 22 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Complex

Velocity Growing

Where it ranks

Overall rank by patents

#693

Across all tracked assignees

Innovation Score

61.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Incyte Corporation hold?

Incyte Corporation holds 652 US granted patents filed between 2015 and 2025, spanning 22 technology areas.

What is Incyte Corporation's Innovation Score?

Incyte Corporation has an Innovation Score of 61.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Incyte Corporation focus on?

Incyte Corporation's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 605 patents. The company has filed patents in 22 CPC subclasses total.

Is Incyte Corporation's patent filing rate increasing or decreasing?

Incyte Corporation's recent filing velocity is +17% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Incyte Corporation's patents?

Incyte Corporation's patents average 26.1 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.

How is the Incyte Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Incyte's 652 grants land it in the top 3% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Incyte ranks #693 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.